Table 1 Population trends in use of oral antidiabetic drugs

Overall

 Patient Number

527,045

579,017

624,540

689,423

736,743

784,132

843,334

903,947

969,161

1,025,646

 Volume/patient (DDDs)_c.

585.94

613.85

640.25

650.54

652.36

651.68

653.71

637.1

630.16

635.59

 Expenditure/patient (US$)_d.

162.80

199.99

219.48

241.64

233.55

232.84

216.31

207.33

205.63

195.34

Subgroups by class

  Volume/patient (DDDs) _c.

 Biguanides

125.11

127.77

129.51

133.68

137.99

141.71

144.18

144.81

143.07

138.19

 Sulfonylureas

449.33

453.46

458.54

444.33

421.16

410.44

399.74

379.16

354.72

325.44

 Alpha-glucosidase inhibitors

3.64

5.97

10.72

13.81

14.67

16.13

18.04

19.35

19.34

19.21

 Thiazolidinediones

3.23

16.04

27.48

34.15

31.15

32.64

36.64

37.44

36.66

38.4

 Dipeptidyl peptidase-4 inhibitors

N/A _b.

N/A

N/A

N/A

N/A

N/A

N/A

N/A

10.17

27.40

 Others_a.

4.63

10.61

14.00

24.56

47.38

51.12

55.12

56.35

66.21

85.93

  Expenditure/patient (US$) _d.

 Biguanides

51.20

51.67

46.46

46.73

46.99

44.42

34.65

32.88

32.47

28.97

 Sulfonylureas

94.38

98.10

95.10

98.36

96.40

94.07

85.00

81.35

74.84

59.13

 Alpha-glucosidase inhibitors

4.94

7.41

12.46

15.81

16.52

17.87

18.54

18.45

17.39

15.06

 Thiazolidinediones

7.70

33.85

53.87

66.64

60.65

62.64

64.40

60.83

55.67

48.42

 Dipeptidyl peptidase-4 inhibitors

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

11.68

31.13

 Others_a.

4.59

8.97

11.59

14.10

12.99

13.84

13.72

13.80

13.58

12.63